Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 01.07.2025       Formycon AG

Press Release // July 1, 2025 Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa Partnership marks a landmark step towards global availability of FYB201 Bio Usawa gets exclusive rights to register and commercialize FYB201/BioUcenta™1 in Sub-Saharan Africa Product launch expected in  [ … ]
Fri, 27.06.2025       Formycon AG

Press Release // 27. June 2025  Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million Interest  [ … ]
Fri, 27.06.2025       Formycon AG

Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014 NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE  [ … ]
Thu, 26.06.2025       Formycon AG

Press Release // June 26, 2025   Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany   Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany Market launch of F [ … ]
Wed, 25.06.2025       Formycon AG

Press Release // June 25, 2025   U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada   Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20 [ … ]
Tue, 24.06.2025       Formycon AG

  Press Release // June 24, 2025 Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period High demand by institutional investors enables early termination of public offering period Subscription period via the Formycon website is now scheduled to end  on 26 June 2025, at 11:59 p.m. CEST Subscription via Deutsche B [ … ]
Fri, 20.06.2025       Formycon AG

Press Release // June 20, 2025 Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse The subscription period via Deutsche Börse AG's DirectPlace is now open and will close on 30 June 2025 at 12:00 p.m. CEST (subject to early closure) The unsecured senior bond has a target volume of €50 million and carries a variable i [ … ]
Wed, 18.06.2025       Formycon AG

Press Release // June 18, 2025   Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities Management provides detailed report on financial year 2024 and provides outlook for 2025 Supervisory Board expands to six members; Klaus Röhrig re-elected Dr. Graham Keith Dixon elected as a new member of the Sup [ … ]
Wed, 18.06.2025       Formycon AG

Press Release // June 18, 2025 Formycon AG: Subscription period for 2025/2029 corporate bond has started Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that the securities prospectus for the newly issued corporate bond 2025/2029 (ISIN NO0013586024 / WKN A4DFJH) has been approved by the Luxembourg finan [ … ]
Tue, 17.06.2025       Formycon AG

Press Release // June 17, 2025 Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next grow [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 08.07.2025, Calendar Week 28, 189th day of the year, 176 days remaining until EoY.